This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nattel, S. Articles by Van Loon, G. Search for Related Content PubMed PubMed Citation Articles by Nattel, S. Articles by Van Loon, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PROPRANOLOL HYDROCHLORIDE

Circulation, Vol 59, 1158-1164, Copyright © 1979 by American Heart Association

ARTICLES

Mechanism of propranolol withdrawal phenomena

S Nattel, RE Rangno and G Van Loon

Nine patients on chronic treatment with propranolol for essential hypertension for 3 months or longer were studied after abrupt discontinuation of the drug. Each patient demonstrated transient supersensitivity to the chronotropic effects of isoproterenol, beginning 2--6 days (median 4 days) after propranolol withdrawal, lasting for 3--13 days (median 6 days), with the maximum sensitivity on day 6. A significantly lower dose of isoproterenol was necessary to increase heart rate 25 beats/min on day 6 (median dose 1.2 microgram, range 0.3--3.4 microgram) compared with after day 14, when sensitivity had stabilized (median dose 2.3 microgram, range 1.4--7.6 microgram). Six patients had transient symptoms (headache, chest pain, palpitations and sweating) after abrupt propranolol withdrawal, coinciding with supersensitivity to isoproterenol in five. Transient increases in plasma catecholamines and blood pressures and sustained increases in heart rate occurred during the period of isoproterenol supersensitivity in most patients, and may have contributed to symptoms noted. The delayed onset and potentially long duration of beta-adrenergic supersensitivity after abrupt propranolol withdrawal have important clinical implications.

This article has been cited by other articles:

				L. Brynne, L. K. Paalzow, and M. O. Karlsson Consequence of Exercise on the Cardiovascular Effects of l-Propranolol in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1201 - 1208. [Abstract] [Full Text]

				K. Katariya, E. DeMarchena, and H. Bolooki Oral amiodarone reduces incidence of postoperative atrial fibrillation Ann. Thorac. Surg., November 1, 1999; 68(5): 1599 - 1603. [Abstract] [Full Text] [PDF]

				L. Brynne, L. K. Paalzow, and M. O. Karlsson Mechanism-Based Modeling of Rebound Tachycardia after Chronic l-Propranolol Infusion in Spontaneous Hypertensive Rats J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 664 - 671. [Abstract] [Full Text]

				K. Malmstrom, G. Rodriguez-Gomez, J. Guerra, C. Villaran, A. Pineiro, L. X. Wei, B. C. Seidenberg, T. F. Reiss, and for the Montelukast/Beclomethasone Study Group* Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma: A Randomized, Controlled Trial Ann Intern Med, March 16, 1999; 130(6): 487 - 495. [Abstract] [Full Text] [PDF]

				T. F. Reiss, P. Chervinsky, R. J. Dockhorn, S. Shingo, B. Seidenberg, T. B. Edwards, and for the Montelukast Clinical Research Study Group Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma: A Multicenter, Randomized, Double-blind Trial Arch Intern Med, June 8, 1998; 158(11): 1213 - 1220. [Abstract] [Full Text] [PDF]